MTND1P22

Across TCGA pan-cancer cohorts, MTND1P22 RNA is linked to patient survival in 10 of 34 cancer types, making it the most broadly survival-associated MTND1P22 data layer.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MTND1P22 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTND1P22 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LUAD, PAAD, and CESC are the cancer types where MTND1P22 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	III,IV	0.196	0.672	<.001	81	view →
PAAD	DFS	Tertile	All	0.195	0.487	.017	36	view →
CESC	OS	Tertile	IV	0.121	0.591	.029	36	view →
SKCM	DFS	Tertile	II,III,IV	0.369	0.595	.025	33	view →
BRCA	DFS	Tertile	III,IV	0.630	0.885	.009	18	view →
ESCA	OS	Quartile	All	0.504	0.940	.008	18	view →
KIRC	DFS	Tertile	III,IV	0.504	0.767	.027	18	view →
READ	DFS	Tertile	III,IV	0.082	0.760	.001	12	view →
BLCA	OS	Tertile	II,III,IV	0.795	0.593	.035	6	view →
OV	DFS	Quartile	IV	0.294	0.499	.035	6	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

MTND1P22–LUAD (OS)

Open the LUAD breakdown →